Gastroesophageal Junction Cancer

The FDA granted fast track designation to ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma and second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma, according to a press release from the drug’s manufacturer.

A randomized phase 3 trial designed to evaluate avelumab as first-line maintenance therapy for patients with unresectable, locally advanced or metastatic HER2-ngative gastric or gastroesophageal junction cancer failed to meet its primary endpoints.

Trifluridine and tipiracil significantly extended PFS and OS compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer, according to results of a subgroup analysis of the randomized phase 3 TAS-102 Gastric Study.